
Zentalis Pharmaceuticals fell 2.2% from $1.39 to $1.36, behind the S&P 500's +3.2%. Its worst day was Mar 27 (−21.3%), and its low came Dec 30 at $1.33.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Zentalis Pharmaceuticals closed at its lowest level of the year, 4.3% below where the year started.
−2.2% · S&P 500 −0.1%
Zentalis Pharmaceuticals shares rose 36.0%, while the S&P 500 fell 0.3%.
+36.0% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Zentalis Pharmaceuticals shares rose 23.4%, while the S&P 500 fell 0.2%.
+23.4% · S&P 500 −0.2%
EPS of $-0.49 beat the $-0.53 estimate on $0.00 revenue.
−21.3%, the year's worst day · S&P 500 −1.7%
Zentalis Pharmaceuticals closed at its highest level of the year, 375.5% above where the year started.
+49.5%, on 46M shares, the year's heaviest volume · S&P 500 −0.1%
EPS of $-0.50 beat the $-0.52 estimate on $0.00 revenue.
0.0% · S&P 500 +0.6%
EPS of $-0.59 missed the $-0.46 estimate on $0.00 revenue.
−15.6% · S&P 500 +0.6%
EPS of $-0.34 beat the $-0.53 estimate on $0.00 revenue.
+3.4% · S&P 500 −0.4%
Where it ended: a close of $1.36 on Nov 20, 2026.
Nothing in the past 12 months.
All ZNTL dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ZNTL and SPY from Benzinga historical bars. Not investment advice.